Last reviewed · How we verify
Amantadin
At a glance
| Generic name | Amantadin |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Target | Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Arteriosclerotic Parkinsonism
- Extrapyramidal disease
- Influenza A Prevention
- Influenza due to Influenza A virus
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
- Nausea
- Dizziness
- Insomnia
- Depression
- Anxiety
- Irritability
- Hallucinations
- Confusion
- Anorexia
- Dry mouth
- Constipation
- Ataxia
Serious adverse events
- Congestive heart failure
- Psychosis
- Cardiac arrest
- Acute respiratory failure
- Neuroleptic malignant syndrome
- Convulsion
- Suicidal attempt
- Suicide
- Anaphylactic reactions
- Pulmonary edema
Key clinical trials
- Benefits of Amantadine in Patients With Coma State
- Action of Amantadine on Post-Stroke Aphasic Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amantadin CI brief — competitive landscape report
- Amantadin updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nice portfolio CI